Contents

Highlights of This Issue 4491

SPECIAL FEATURES

4493  
Volumes to Learn: Advancing Therapeutics with Innovative Computed Tomography Image Data Analysis  
Michael L. Maitland  
See article p. 4647

CCR Translations

4493  
Volumes to Learn: Advancing Therapeutics with Innovative Computed Tomography Image Data Analysis  
Michael L. Maitland  
See article p. 4647

Molecular Pathways

4496  
X-linked Inhibitor of Apoptosis: A Chemoresistance Factor or a Hollow Promise  
Hamid Kashkar

4503  
Targeting Cell Division Cycle 7 Kinase: A New Approach for Cancer Therapy  
Alessia Montagnoli, Jürgen Moll, and Francesco Colotta

CCR Focus

4503  
Targeting Cell Division Cycle 7 Kinase: A New Approach for Cancer Therapy  
Alessia Montagnoli, Jürgen Moll, and Francesco Colotta

4506  
Epigenetic Modifications in Double-Strand Break DNA Damage Signaling and Repair  
Dorine Rossetto, Andrew W. Truman, Stephen J. Kron, and Jacques Côté

4553  
“Contextual” Synthetic Lethality and/or Loss of Heterozygosity: Tumor Hypoxia and Modification of DNA Repair  
Norman Chan and Robert G. Bristow

HUMAN CANCER BIOLOGY

4553  
“Contextual” Synthetic Lethality and/or Loss of Heterozygosity: Tumor Hypoxia and Modification of DNA Repair  
Norman Chan and Robert G. Bristow

4561  
Regression of Excision Repair Cross-Complementation Group 1 by Snail Contributes to Cisplatin Resistance in Head and Neck Cancer  

4571  
System-Level Analysis of Neuroblastoma Tumor-Initiating Cells Implicates AURKB as a Novel Drug Target for Neuroblastoma  
Olena Morozova, Milijana Vojvodic, Natalie Grinshtein, Loen M. Hansford, Kim M. Blakely, Alexandra Maslova, Martin Hirst, Timothee Cezard, Ryan D. Morin, Richard Moore, Kristen M. Smith, Freda Miller, Paul Taylor, Nina Thiesen, Richard Varhol, Yongjun Zhao, Steven Jones, Jason Moffat, Thomas Kislinger, Michael F. Moran, David R. Kaplan, and Marco A. Marra

4583  
A Novel Chemoimmunomodulating Property of Docetaxel: Suppression of Myeloid-Derived Suppressor Cells in Tumor Bearers  
Krithika N. Kodumudi, Karrune Woan, Danielle L. Gilvary, Eva Sahakian, Sheng Wei, and Julie Y. Djeu

4595  
Inhibitory Effect of Silibinin against Azoxymethane-Induced Colon Tumorigenesis in A/J Mice  
Kameswaran Ravichandran, Balaiya Velmurugan, Mallikarjuna Gu, Rana P. Singh, and Rajesh Agarwal

The Journal of Clinical and Translational Research

September 15, 2010 • Volume 16 • Number 18

www.aacrjournals.org
<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>4607</td>
<td>Assessment of Vaccine-Induced CD4 T Cell Responses to the 119-143 Immunodominant Region of the Tumor-Specific Antigen NY-ESO-1 Using DRB1*0101 Tetramers</td>
<td>Maha Ayyoub, Pascale Pignon, Danijel Dojcicinovic, Isabelle Raimbaud, Lloyd J. Old, Immanuel Luescher, and Danila Valmori</td>
</tr>
<tr>
<td>4625</td>
<td>Correlated Expression of CD47 and SIRPA in Bone Marrow and in Peripheral Blood Predicts Recurrence in Breast Cancer Patients</td>
<td>Makoto Nagahara, Koshi Mimori, Akemi Kataoka, Hidetsu Ishii, Fumiaki Tanaka, Tsuyoshi Nakagawa, Takanobu Sato, Shinji Ono, Kenichi Sugihara, and Masaki Mori</td>
</tr>
<tr>
<td>4636</td>
<td>Jumonji Domain Containing 1A Is a Novel Prognostic Marker for Colorectal Cancer: In vivo Identification from Hypoxic Tumor Cells</td>
<td>Mamoru Uemura, Hirofumi Yamamoto, Ichiro Takanawa, Koshi Mimori, Hideyuki Hemmi, Tsunekazu Mitsuhashi, Masatada Ikeda, Mitsugu Sekimoto, Nariaki Matsuya, Yuichiro Dokji, and Masaki Mori</td>
</tr>
<tr>
<td>4647</td>
<td>A Pilot Study of Volume Measurement as a Method of Tumor Response Evaluation to Aid Biomarker Development</td>
<td>Binsheng Zhao, Geoffrey R. Oxnard, Chaya S. Moskowitz, Mark G. Kris, William Pao, Pingzhen Guo, Valerie M. Rusch, Marc Ladanyi, Naiyer A. Rizvi, and Lawrence H. Schwartz</td>
</tr>
<tr>
<td>4666</td>
<td>An Open-Label, Phase I Study of the Polo-like Kinase-1 Inhibitor, BL 2536, in Patients with Advanced Solid Tumors</td>
<td>Ralf-Dieter Hofheinz, Salah-Eddin Al-Batran, Andreas Hochhaus, Elke Jäger, Volker L. Reichardt, Holger Fritsch, Dirk Trommehausen, and Gerd Munzert</td>
</tr>
<tr>
<td>4675</td>
<td>Expression of Receptors for Luteinizing Hormone-Releasing Hormone (LH-RH) in Prostate Cancers following Therapy with LH-RH Agonists</td>
<td>Stephen V. Liu, Andrew V. Schally, Debra Hawes, Shigang Xiong, Laden Fazli, Martin Gleave, Jie Cai, Susan Grosvenor, Frank Brands, Juergen Engel, and Jacek Pinski</td>
</tr>
<tr>
<td>4681</td>
<td>Correction: A Phase I Pharmacologic Study of Necitumumab (IMC-11F8), a Fully Human IgG1, Monoclonal Antibody Directed against EGFR in Patients with Advanced Solid Malignancies</td>
<td>See commentary p. 4493</td>
</tr>
</tbody>
</table>
ABOUT THE COVER

Clinical Use of γH2AX and PAR: Image of an anagen hair bulb plucked from the scalp of a cancer patient 24 hours after drug infusion. γH2AX antibody reveals DNA double-strand breaks (green foci) in cell nuclei (red). Imaged using a Nikon PCM 2000 laser scanning confocal microscope. For details, please see the article by Redon and colleagues on p. 4532 of this issue.
Clinical Cancer Research

16 (18)


| Updated version | Access the most recent version of this article at: http://clincancerres.aacrjournals.org/content/16/18 |

| E-mail alerts | Sign up to receive free email-alerts related to this article or journal. |
| Reprints and Subscriptions | To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org. |
| Permissions | To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org. |